The treatment of advanced non-small cell lung cancer has been with systemic chemotherapy and usually consists of a platinum doublet chemotherapy. The identification of somatic driver mutations has resulted in new drugs that target these mutations. This report discusses the two most important new targeted therapy drugs for the treatment of advanced non-small cell lung cancer that have these driver mutations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/rccm.201301-0189PP | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Controversial influence of adjuvant immunotherapy in survival outcomes for patients with non-small cell lung cancer with major/complete pathologic response.
J Thorac Cardiovasc Surg
December 2024
Department of Medical Oncology, Elazig Fethi Sekin City Hospital, Elazig, Turkey.
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens.
Curr Issues Mol Biol
December 2024
Department of Pathology, Faculty of Medicine, Prince of Songkhla University, Hat Yai 90110, Songkhla, Thailand.
This study aimed to generate Car- and Pac-resistant cell lines from the human lung adenocarcinoma H1792 cell line, designated as H1792/Car and H1792/Pac, and perform transcriptome sequencing to identify potential targets. Common differentially expressed genes (Co-DEGs) in both resistant cell lines were identified, followed by hub gene identification. Online validation was conducted through GEPIA and Kaplan-Meier Plotter platforms, with experimental validation performed using real-time quantitative PCR (RT-qPCR).
View Article and Find Full Text PDFTreatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases.
Curr Issues Mol Biol
November 2024
Internal Medicine Clinic "Akta Medica", 11000 Belgrade, Serbia.
Lung cancer represents the most common cause of cancer-related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases have worse prognosis, with an overall survival (OS) from three to six months. The majority of them have a poor response to chemotherapy, and the data are controversial regarding the response to immunotherapy.
View Article and Find Full Text PDFLong-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases.
Curr Issues Mol Biol
November 2024
Internal Medicine Clinic "Akta Medica", 11000 Belgrade, Serbia.
Lung cancer represents the most common cause of cancer related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases (LM) have worse prognosis with an overall survival (OS) of three to six months. The aim of this study was to investigate long-term outcomes in patients with EGFR mutated (EGFRmut) lung adenocarcinoma as well as the presence of LM.
View Article and Find Full Text PDFMetabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report.
Curr Oncol
December 2024
Radiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, Italy.
A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!